Analyst predicts increase in sales of cold and flu medications
NEW YORK Citi analyst Deborah Weinswig last week noted that drug stores and cold medicine distributors may be looking toward rosy sales after Valentines Day given the higher incidence of colds and flu of late. “Week 19 of the flu season (week ending Feb. 2) was the first time since February 2005 when more than 30 states experienced widespread flu outbreaks,” she wrote. “We believe that the recent surge in flu activity is a significant positive for both Rx and front-end comps in February. “
Nationwide, during week 19 of the flu season, 5.1 percent of patient visits reported through the U.S.
Influenza Sentinel Provider Surveillance Network were due to influenza-like illness. And 3.2 percent of patient visits to Department of Veterans’ Affairs and Department of Defense outpatient treatment facilities were for acute respiratory illness. The percentage of visits for ILI was above the national baseline of 2.2 percent, and the percentage of visits for ARI was at the national baseline of 3.2 percent.
Isma Benattia named Wyeth Consumer Healthcare head of global R&D
MADISON, N.J. Wyeth Consumer Healthcare announced that Isma Benattia has been named executive vice president of Global Research and Development, effective immediately.
In her new role, Benattia will be in charge of bringing new products to market and managing regulatory necessities regarding Wyeth’s over-the-counter products.
Benattia has served at Wyeth Pharmaceuticals since 2003, where she most recently was vice president in charge of Global Labeling. She previously held the position of executive medical director of neuroscience, where she played a leading role in managing scientific and regulatory issues involving Effexor, Wyeth’s second largest brand in terms of global revenue.
Prior to joining Wyeth, Benattia led global clinical programs for major products at Pfizer and Eli Lilly. She holds Master’s degrees in Pharmacology and Psychotropic Drugs; Methodology of Clinical Research and Medical and Marketing Management.
Study shows Relacore may reduce acne flare-ups
NEW YORK Carter Reed on Friday released studies that suggests its dietary supplement diet aid Relacore may be useful in reducing acne flare-ups.
“One of the reasons Relacore has been so successful is because people buy it along with other diet pills or to use in conjunction with any sensible diet and exercise plan,” stated Gina Daines, Carter-Reed’s director of marketing. “Now when it comes to acne, we’re seeing the same phenomenon—those who buy popular anti-acne treatments, like Proactive, are picking up a bottle of Relacore to expand and complete their anti-acne regimen, using Relacore to help prevent the stress-related increase, duration, frequency and severity of acne flare-ups.”